Oncozenge (Sweden) Insiders
| ONCOZ Stock | SEK 3.78 0.12 3.08% |
Oncozenge employs about 2 people. The company is managed by 4 executives with a total tenure of roughly 5 years, averaging almost 1.0 years of service per executive, having 0.5 employees per reported executive. Breaking down Oncozenge's management performance can provide insight into the firm performance.
| Mark Beveridge Insider Chief Officer |
| Markus MD Insider Chief Officer |
Oncozenge |
Oncozenge Management Team Effectiveness
Oncozenge's management efficiency ratios could be used to measure how well Oncozenge manages its routine affairs as well as how well it operates its assets and liabilities.Oncozenge Workforce Comparison
Oncozenge AB is considered to be number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 101. Oncozenge claims roughly 2.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.
Oncozenge AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Oncozenge AB Price Series Summation is a cross summation of Oncozenge price series and its benchmark/peer.
Oncozenge Notable Stakeholders
An Oncozenge stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oncozenge often face trade-offs trying to please all of them. Oncozenge's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oncozenge's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mark Beveridge | Chief Officer | Profile | |
| Markus MD | Chief Officer | Profile | |
| Paul MSc | Chief Officer | Profile | |
| Pirkko Tamsen | Chief Officer | Profile |
About Oncozenge Management Performance
The success or failure of an entity such as Oncozenge AB often depends on how effective the management is. Oncozenge management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oncozenge management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oncozenge management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
OncoZenge AB , a pharmaceutical company, develops healthcare products for cancer supportive care. OncoZenge AB is a subsidiary of Moberg Pharma AB . OncoZenge is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Oncozenge's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncozenge AB. Check Oncozenge's Beneish M Score to see the likelihood of Oncozenge's management manipulating its earnings.
Oncozenge Workforce Analysis
Traditionally, organizations such as Oncozenge use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oncozenge within its industry.Oncozenge Manpower Efficiency
Return on Oncozenge Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.9M | |
| Net Loss Per Executive | 971.5K |
Additional Tools for Oncozenge Stock Analysis
When running Oncozenge's price analysis, check to measure Oncozenge's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncozenge is operating at the current time. Most of Oncozenge's value examination focuses on studying past and present price action to predict the probability of Oncozenge's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncozenge's price. Additionally, you may evaluate how the addition of Oncozenge to your portfolios can decrease your overall portfolio volatility.